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1. Introduction
A specific feature of hematopoietic stem cells (HSC) is the potency to supply all types of
blood cells throughout life by self-renewal and differentiation. Bone marrow (BM) is actively
producing differentiated blood cells with enormous cellular turnover. Under homeostatic
state, primitive HSC in adult BM divide only rarely and are located in specialized regulatory
environment to avoid exhaustion and DNA damages that are supposed to cumulatively de‐
velop hematopoietic disorders such as myelodysplastic syndrome or leukemia. However,
those quiescent HSC can be proliferative on demand, particularly on systemic infection or
myelo-suppressive treatment. Therefore, elaborate mechanisms regulating the self-renewal
and differentiation of BM HSC is indispensable to maintain normal hematopoiesis through‐
out life. The fluctuating feature of HSC is thought to be associated with their regulatory en‐
vironment, generally called “HSC niche”.
Technical improvement for purifying authentic HSC from heterogeneous cellular popula‐
tions is necessary to understand the features of those extremely rare and precious cells and
promote their therapeutic application. Many studies have attempted to identify their specif‐
ic markers, and now flow cytometry- based strategies have made it possible to sort HSC
with high purity in mice. However, the source and the stage of HSC change along ontogeny,
which consequently influence not only their functional abilities but also their surface immu‐
nophenotypes. In the light of fluctuating nature of HSC, it should be very important to un‐
derstand their phenotype specific to reconstitution activity of the immune system after
myelo-suppressive events.
Hematopoietic cells and endothelial cells are both generated from mesodermal precursor
cells in ontogeny [1]. Thereafter, HSC pool is formed in several anatomical sites such as aor‐
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ta-gonad-mesonephros (AGM) region, placenta, fetal liver, and BM. At the early stage of on‐
togeny, HSC frequently undergo symmetrical and/or asymmetrical division to form entire
hematopoietic system compared to adult HSC. Those early HSC and endothelial cells bear
some common surface antigens, of which expression levels on HSC decline along aging. In‐
terestingly, some of the endothelial-related surface molecules revive on HSC after BM in‐
jury, when the cells actively divide to regenerate BM cells.
We recently reported endothelial cell-selective adhesion molecule (ESAM) as a new marker
for HSC [2]. Interestingly, ESAM levels on HSC clearly mirror the shift of HSC between qui‐
escence and activation, and the up-regulation amplitude is prominent in comparison to oth‐
er HSC-related antigens [3]. Furthermore, we found that ESAM is functionally indispensable
for HSC to re-establish homeostatic hematopoiesis [3]. In this chapter, we review a wealth of
information about traditional HSC markers, and introduce our recent findings.
2. Development of the strategy for purifying HSC from murine BM
HSC are defined by their capacity for both self-renewal and differentiation into all the blood
cell types. In 1988, Spangrude et al. reported lineage (Lin; Mac-1, Gr-1, B220, CD4, and CD8)-
Thy-1Lo Sca-1+ cells in mouse BM as a multipotent HSC population. When these cells were
transplanted into lethally irradiated mice, only thirty cells were sufficient to save 50% of the
recipient mice and reconstitute B, T, and myeloid cells [4]. In 1991, Ogawa et al. reported that
half of the c-kit+ BM cells do not express Lin (Mac-1, Gr-1, Ter119, and B220) markers, and c-
kit- population do not include hematopoietic progenitor cells [5]. From then on, Lin- Sca-1+ c-
kit+ (LSK ) cells has been used as the population in which HSC are highly concentrated [6,7].
HSC can be functionally classified as either long-term (LT-HSC) or short-term (ST-HSC) ac‐
cording to their capacity to give rise to life-long or transient hematopoiesis. Osawa et al.
showed that CD34+ LSK cells are capable of only short-term multilineage differentiation. In
contrast, CD34-/Lo LSK cells have long-term multilineage reconstitution capacity. They also
showed that CD34-/Lo LSK cells can differentiate into CD34+ LSK cells [7]. LSK fraction also
can be divided into two populations by expression level of Flk-2. While LT-HSC are en‐
riched in the Flk-2- LSK fraction, the Flk-2+ LSK cells are mainly ST-HSC [8].
While the techniques of purifying HSC by use of surface markers had been promoted,
Goodell et al. reported the method for purifying HSC without use of surface markers.
Hoechst33342 is a fluorescent dye which binds to DNA of live cells. When Hoechst fluores‐
cence on whole BM was examined simultaneously at two emission wavelength (red and
blue), one population of cells with increased ability to efflux Hoechst dye was observed.
Goodell et al. named it “side population (SP)”, and showed that a majority of HSC were en‐
riched in the SP by competitive repopulating experiments [9]. Subsequently, Matsuzaki et al.
described a method of further purifying HSC by combining staining with antibodies to sur‐
face molecules with the Hoechst dye efflux. They showed the fraction of cells with the stron‐
gest dye efflux activity (termed as “Tip”-SP) has the highest marrow-repopulating activity.
While 20% of “Tip”-SP cells are primitive hematopoietic cells, more than 90% of “Tip”-SP
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CD34- KSL cells, which are extremely rare, representing only 0.001-0.01% of BM mononu‐
clear cells, are almost pure primitive hematopoietic cells that have long-term multilineage
repopulating potency [10]. More recently, the endothelial protein C receptor CD201 was
found as a new endothelial-related HSC marker which marks approximately 70% of the SP
cells. The marker seems to be useful to purify LT-HSC among the SP cells because only the
CD201 + subpopulation exhibited repopulating ability [11].
In recent years, Kiel et al. demonstrated that a simple combination of SLAM family markers
(CD150, CD244 and CD48) could enrich primitive murine HSC. That is, one out of every 4.8
(21%) of CD150+ CD48- cells from young adult murine BM gave long-term multilineage re‐
constitution [12]. Furthermore, they observed that one out of every 2.1 (47%) of CD150+
CD48- LSK cells had long-term multilineage reconstituting potential. Approximately 15~20%
of CD150+ CD48- LSK or CD34- CD150+ CD48- LSK cells, which divide only 5-6 times during
the mouse life span, have more long-term repopulating potential than other cells [13,14]. We
can now purify dormant LT-HSC from murine BM using the SLAM family markers in com‐
bination with LSK gating. The information regarding murine HSC markers is summarized
in Table 1.
Markers References
Lin- Thy-1Lo Sca-1+ Spangrude et al. Science (1988) [4]
CD34-/Lo LSK Osawa et al. Science (1996) [7]
Side population (SP) Goodell et al. J Exp Med (1996) [9]
Lin- Rho- SP Uchida et al. Exp Hematol (2003) [15]
Tip-SP LSK Matsuzaki et al. Immunity (2004) [10]
CD48- CD150+ CD41- LSK Kiel et al. Cell (2005) [12]
BrdU and histone 2B-retaining CD48- CD150+ CD34- LSK Wilson et al. Cell (2008) [14]
Histone 2B-retaining CD48- CD150+ LSK Foudi et al. Nat Biotechnol (2009) [13]
Lin, lineage; Rho, Rhodamine-123; LSK, Lin- Sca-1+ c-kit+
Table 1. Markers for adult murine hematopoietic stem cells.
3. HSC markers during developmental stages
HSC markers during developmental stages are not identical to those of adult HSC. In the
embryo, functional HSC that can reconstitute hematopoiesis in adult recipients are firstly
found in the aorta-gonad-mesonephros (AGM) region at approximately embryonic day 10
(E10) [16-18]. Many reports have demonstrated that those earliest authentic HSC bud from
endothelial-related cells, which involve the concept of “hemangioblast” or “hemogenic en‐
dothelium” [19-23]. In fact, emerging HSC and endothelial cells share various surface mark‐
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ers such as CD34 and VE-cadherin that do not mark adult murine LT-HSC [24-26]. On the
contrary, the emerging HSC do not express either Sca-1 or CD45, a pan-hematopoietic mark‐
er [19,27]. Interestingly, those developing HSC express CD41/Integrin-αv, a marker for meg‐
akaryocytes [28].
Although HSC do not emerge in the fetal liver de novo, the organ is the main site of HSC
expansion before birth. Circulating HSC seed in the fetal liver, where they robustly expand
and differentiate. Indeed, numbers of HSC increase ~40-fold in the fetal liver between E12
and E16 [29]. Unlike the emerging HSC in the AGM region, HSC in fetal liver express CD45
and Sca-1. Morrison et al. showed that HSC are highly enriched in Thy1Lo Sca-1+ Lin- Mac1+
fraction of fetal liver cells [30]. His group later demonstrated that the SLAM family markers
(CD150+ CD48-) are also useful to enrich for HSC in E14.5 fetal liver just as in adult BM by
the fact that 37% of CD150+ CD48- Sca-1+ Lin- Mac1+ fetal liver cells had long-term reconsti‐
tuting capacity [31]. Although the expression levels of AA4.1 and VE-cadherin are very high
at the early stage of fetal hematopoiesis, they become gradually down-regulated after E12-
E13 [32,33]. Interestingly, the phenotype of HSC in fetal liver rapidly changes after E16,
when their number is reaching to a plateau level [30]. Recently, our group reported ESAM
as a novel HSC marker in fetal liver (see below). HSC markers during mouse ontogeny are
summarized in Table 2.
Fetal age Location Markers References
E8.5-E10.5 AGM region CD41+ CD34+ CD45- VE-
cadherin+ Sca-1- AA4.1+
ESAM+
Petrenko et al. Immunity (1999) [33], Hsu et al.
Blood (2000) [34], Baumann et al. Blood (2004) [24],
Fraser et al. Exp Hematol (2002) [25], Ogawa Exp
Hematol (2002) [26], de Brujin et al. Immunity
(2002) [19], Mikkola et al. Blood (2003) [28],
Matsubara et al. J Exp Med (2005) [27], Kim et al.
Blood (2005) [32], Kim et al. Blood (2006) [31],
Mansson et al. Immunity (2007) [35], Yokota et al.
Blood (2009) [2]
E11.5-E16.5 Fetal liver CD41- CD34+ CD45+ CD31+
Sca-1+ Mac1+ Tie-2+ Flt3- c-kit+
AA4.1+ VE-cadherin+/- CD150+
CD48- ESAM+
Table 2. Markers for hematopoietic stem cells during mouse ontogeny.
Adult and fetal HSC are not the same with regard to not only surface phenotypes but also
cell-cycle status. Recent studies have shown that the long-term reconstituting activity of
adult BM is sustained mostly in very quiescent HSC [13,14]. However, cycling HSC from the
fetal liver give rise to higher levels of reconstitution than HSC obtained from adult BM
[30,36]. The microenvironments, known as “HSC niches”, are believed to influence cell-cycle
status of HSC, and adult HSC niches in BM seem to be different from HSC niches in the fetal
liver [12,37-40]. More precise analyses of hematopoietic environment in the embryo should
give us valuable information regarding what are the imperative conditions for HSC expan‐
sion and how the alteration of surface molecules on HSC is functionally involved in that
process. Furthermore, such cell surface antigens that mirror the HSC state are invaluable for
understanding the relationship between HSC and their niches.
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4. Niche signals regulating HSC pool
We think it seems meaningful to deal with the “HSC niche” briefly here, although another
chapter in this book provides more detailed information about its function. Molecular cross‐
talk between HSC and their niches has been considered to be important to provide signals
for self-renewing division that maintain HSC pool. Although precise mechanisms regulating
HSC status still remain unknown, there are accumulating evidences to involve several spe‐
cific cells, or cytokines and chemokines secreted from stromal cells in this process.
In 1994, human osteoblasts were shown to maintained hematopoiesis by constitutively pro‐
ducing G-CSF in vitro [41]. In the first decade of the 21st century, a notion that connects os‐
teoblasts with the HSC niche rapidly developed. Parathyroid hormone (PTH), which is a
main regulator of calcium homeostasis, was reported to increase in the number of both os‐
teoblasts and HSC, suggesting osteoblasts as the candidate for HSC niche [42]. In addition, it
was also reported that BrdU label retaining cells (LRC) were attached to spindle-shaped N-
cadherin+ osteoblasts (SNO) cells, and that bone morphogenetic protein (BMP) signalling
controlled the number of HSC by regulating SNO cells [37].
On the other hand, Kiel et al. reported that many CD150+ CD48- CD41- Lin- LT-HSC were in
contact with sinusoidal endothelial cells in spleen or BM, suggesting that endothelial cells
are also essential components of the HSC niche. With regard to cytokine-chemokine sinal‐
ings, the CXC chemokine ligand 12 (CXCL12) -CXC chemokine receptor 4 (CXCR4) pathway
was found to be important. In vitro, HSC expressing CXCR4 migrate in response to CXCL12
which is the ligand for CXCR4 [43]. Nagasawa’s laboratory reported that a majority of
CD150+ CD48- CD41- HSC were in contact with CXCL12-abundant reticular (CAR) cells, and
that the numbers of HSC in CAR cell-depleted mice were reduced in comparison with con‐
trol mice. These data are supportive of the idea that CXCL12-CXCR4 pathway is essential
for HSC pool [39,44]. Recently, Yamazaki et al. reported TGF- β as a candidate niche signal
in the control of HSC hibernation [45]. The same group advocated that glial cells, regulating
activation of TGF-β signal, might be a component of the HSC niche in adult BM and main‐
tain HSC hibernation [46].
5. Differences between murine and human HSC markers
A critical issue that has been an obstacle in applying the information of murine HSC to hu‐
man is the lack of common HSC markers between the two species. Researchers described
above have made great efforts to purify authentic HSC from murine hematopoietic organs.
Owing to those achievements, we can now sort LT-HSC with very high purity from the
murine BM. However, human HSC cannot be purified with the same markers. Human HSC
do not express Sca-1 or CD150 that are the established HSC markers in mice. In addition, the
long-term HSC of human BM are enriched in CD34+ CD38- population, while murine BM
HSC are CD34- CD38+ [26,47,48].
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Early studies in the 1980s proved by using monoclonal antibody technique that CD34+ popu‐
lation of human BM includes immature hematopoietic progenitors [49-51]. Berenson et al.
showed that autologous CD34+ cells enriched from baboon BM were able to reconstitute nor‐
mal hematopoiesis after lethal irradiation. Animals transplanted with CD34- cells, however,
did not recover sufficient hematopoiesis [52]. Afterwards, over the past two decades, CD34-
positive has been used as a reliable marker for human HSC or hematopoietic progenitor
cells (HPC). Indeed, transplantation of CD34+ cells obtained from donor BM, peripheral
blood, or cord blood (CB) can provide long-term and multilineage hematopoietic reconstitu‐
tion in recipients.
As CD34 marks human HSC as well as more differentiated progenitor cells, researchers
have sought additional markers to further enrich CD34+ population for LT-HSC. Baum et al.
reported that CD90/Thy-1+ population in Lin- CD34+ cells contained pluripotent hemato‐
poietic progenitors [53]. Recently a series of studies of John Dick’s laboratory have success‐
fully improved the techniques to more purify human HSC. His group reported that human
HSC activity was restricted to CD49f+ fraction, and that single Lin- CD34+ CD38- CD45RA-
Thy-1+ Rhodamin123Lo CD49f+ cells in CB cells accomplished multilineage engraftment in
immune-deficient mice [54].
While LT-HSC can be enriched mainly in the CD34+ population, the possibility that CD34-
cells also contain LT-HSC has been reported. Bhatia et al. showed human CD34- population
in Lin- cells of BM and CB also contained LT-HSC [55]. It should be important to compare
the features of primate CD34- HSC with those of murine CD34- LSK cells. In addition, a new
positive marker for human HSC could resolve the relationship between the CD34+ and
CD34- HSC. Markers for human HSC are summarized in Table 3.
Markers References
CD34+ Berenson et al. J Clin Invest (1988) [52]
CD34+ CD38- Terstappen et al. Blood (1991) [48]
CD34+ Lin- Thy-1+ Baum et al. Proc Natl Acad Sci USA (1992) [53]
Lin- CD34- CD38- Bhatia et al. Nat Med (1998) [55]
CD34+ CD38- Lin- RhoLo McKenzie et al. Blood (2007) [47]
Lin- CD34+ CD38- CD45RA- Thy-1+ RhoLo CD49f+ Notta et al. Science (2011) [54]
Table 3. Markers for human hematopoietic stem cells.
6. Differences between quiescent and activated HSC markers
After  mice are  treated with cytotoxic  agents  or  irradiation,  most  of  cell-cycling hemato‐
poietic  cells  are  killed  and  dormant  primitive  HSC  start  to  proliferate.  The  patterns  of
surface molecules expressed on activated HSC change from those under steady-state con‐
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dition.  While  activated  HSC  increase  the  expression  level  of  Sca-1,  CD150,  Tie2,  Endo‐
glin,  Mac-1,  and  CD34,  they  clearly  decrease  that  of  c-kit  and  N-cadherin  [26,56,57].
Some  endothelial-related  antigens,  which  mark  actively  dividing  fetal  HSC  but  do  not
mark quiescent adult HSC, are up-regulated again on the activated HSC after BM injury.
The characteristics of those activated HSC are reminiscent of fetal HSC. Since no obvious
phenotypes  have  been  documented  regarding  CD34  or  CD150-deficient  mice,  how  the
up-regulation of those molecules contributes to the functions and/or characteristics of ac‐
tivated  HSC  remains  unknown  [12,58].  Tie2  and  Endoglin,  which  are  the  receptors  for
angiopoietin and TGF, respectively, might transduce important signals to regulate divid‐
ing speed of  HSC. If  we could accurately monitor  the fluctuation of  HSC status with a
set  of  surface  markers,  that  should yield significant  insight  regarding HSC biology and
HSC  applications  for  clinical  purposes.  As  a  very  recent  achievement,  our  group  has
demonstrated that ESAM is a useful marker for activated HSC.
7. An endothelial-related antigen ESAM as a new novel HSC marker
We previously reported sorting strategy of HSC and early lymphoid progenitors (ELP) from
Rag1/GFP knockin mice [59,60]. We searched for genes whose expression levels are signifi‐
cantly different between Rag1- c-kitHi Sca-1+ HSC and Rag1Lo c-kitHi Sca-1+ ELP by analyzing
micro-array data. Among the HSC related genes ESAM drew our attention because its tran‐
scripts were conspicuous in the HSC fraction whereas the expression was drastically down-
regulated in the ELP fraction. ESAM molecule is an immunoglobulin superfamily protein
that is exposed on cell surface and originally identified as an endothelial cell-specific protein
[61,62]. We found the ESAMHi population of Rag1- c-kitHi Sca-1+ fraction of E14.5 fetal liver
was highly enriched for LT-HSC compared with ESAM-/Lo subset. Among Rag1/GFP- Tie2Hi
E10.5 AGM cells, only ESAM+ cells could effectively produce both CD19+ lymphoid cells and
Mac1+ myeloid cells 2.
ESAM is also expressed on adult murine HSC-enriched fraction in BM. Ooi et al. reported
that ESAM+ Sca-1+ Lin- BM cells could more effectively enrich for LT-HSC than the conven‐
tional HSC-enriched LSK cells, and that ESAM expression on HSC was conserved among
various mouse strains [63]. ESAM levels on HSC are variable according to developing stages
or advancing age. Interestingly, the intensity of ESAM expression on HSC gradually in‐
creased with age after reaching adulthood 2. Based on these observations, ESAM can be a
novel murine HSC marker throughout life including developmental stages.
The usefulness of ESAM as a HSC marker has been further enhanced by the findings that its
expression in human HSC is also detected. Ooi et al. reported that robust levels of ESAM
transcripts were detected in Lin- CD34+ CD38- CD90+ human HSC, while the levels of ESAM
transcripts in unfractionated CB cells were very low [63]. We have confirmed that ESAM ex‐
pression is clearly detectable on human CB CD34+ cells by using its specific antibody and
flow cytometry [64]. In addition, our group has also observed that the marker is effective as
well for adult human HSC in both BM and mobilized peripheral blood. (Ishibashi et al.
manuscript in preparation).
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8. ESAM monitors HSC status between quiescence and self-renewal
As mentioned above, the expression pattern of surface antigens on activated HSC after BM
injury substantially differs from that on quiescent HSC. Administration of an anti-cancer
drug 5-FU causes apoptosis of dividing hematopoietic progenitors, while the treatment re‐
tains quiescent LT-HSC and induces their proliferation afterward. We have observed that re‐
markable increase of ESAM expression levels transiently occurs on BM HSC after a 5-FU
treatment. Furthermore, we have proved that the long-term hematopoietic reconstituting ac‐
tivity is almost exclusive to LSK cells bearing up-regulated ESAM expression [3].
Although expression levels of CD34, Tie2, and Endoglin on LSK show modest increases af‐
ter 5-FU injection, up-regulation of ESAM is remarkable (Figure 1). Why does ESAM need to
revive so vividly on HSC after BM injury? One possible reason is that HSC might directly
receive necessary signals which regulate self-renewal or differentiation via interaction with
ESAM. Another possibility is that high amounts of ESAM might change the polarity or mo‐
bility of HSC, which consequently facilitate them to settle in adequate supporting niches
(Figure 2). The latter assumption is likely because Wegmann and colleagues reported that
ESAM deficiency causes insufficient Rho signalling in endothelial cells, which regulates the
stabilization of endothelial tight junctions [65]. Rho is also expressed in hematopoietic pro‐
genitors and involved in their polarity and mobility [66]. It is noteworthy that more than
80% of ESAMHi HSC were located around perivascular areas in 5-FU-treated BM3.
In any case, ESAM is likely to play an indispensable role during the recovery from BM in‐
jury. Because, while ESAM deficient mice do not show significant hematopoietic defects in
homeostatic stage, the mice fall into severe and prolonged pancytopenia after myelo-sup‐
pressive treatment. In particular, they suffer from severe anemia and frequently die before
hematopoietic recovery. Our findings indicate that ESAM not only marks activated HSC but
also functionally supports their proliferation and differentiation.
Figure 1. Overview of cell surface expression levels on quiescent steady-state HSC and activated HSC.
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Figure 2. Tentative models of ESAM function. (A) In this model, activated HSC directly receive necessary signals which
regulate self-renewal or differentiation via interaction with ESAM. (B) In this model, HSC change their polarity or mobi‐
lity, and consequently, they can move to appropriate niches. ESAM may function as an adhesion factor between HSC
and their niches.
9. Concluding remarks
In this chapter, we summarized achievements for identification of murine and human HSC,
and introduced endothelial-related antigen ESAM as a useful HSC marker. While we can
now purify murine LT-HSC with high efficiency, characterization of human HSC is less well
understood because of insufficient information about surface antigens. Over two decades
CD34-positive has been believed to be a reliable marker for human HSC/HPC. Although
there are now accumulating evidences regarding surface markers to further enrich human
LT-HSC in the CD34+ fraction, more information about human HSC-related antigens should
be useful to improve strategies of HSC application to the clinical medicine. Although ESAM
was originally identified with an endothelial specific molecule, we have demonstrated that
it is a positive marker for both murine and human HSC. Because ESAM seems to play an
essential role for hematopoietic recovery after BM injury, it would be significant to elucidate
downstream signals of ESAM, and the possibility of ESAM as niche components. In addi‐
tion, we now know that the up-regulation of ESAM is observed on cultured murine embry‐
onic stem (ES) cells cultured in the OP9 system which recapitulate very primitive stages of
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hematopoietic development [67] (Doi et al. manuscript in preparation). ESAM might have
some roles in embryonic hematopoiesis at very early stages. As an on-going study, we are
now investigating whether ESAM can be a useful biomarker for inducing hematopoietic
cells from ES or induced pluripotent stem cells.
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